The Myeloma Beacon Staff's Archive

The Myeloma Beacon Staff has written 715 article(s) .

[ by | Sep 3, 2014 7:39 am | 9 Comments ]
Dyclonine, The Active Ingredient In Sucrets, May Enhance The Anti-Myeloma Activity Of Velcade

Results of a small preclinical study conducted at the Karmanos Cancer Center in Detroit indicate that the oral anesthetic dyclonine may enhance the anti-myeloma activity of Velcade.

Dyclonine is the active ingredient in the Sucrets brand of sore throat lozenges, which are sold over-the-counter in drugstores and other retailers in Canada and the United States.  Sucrets lozenges are marketed by Insight Pharmaceuticals.

The Karmanos researchers conducted laboratory tests of dyclonine’s activity against the so-called “RPMI8226″ line of myeloma cells, which …

Tags: , , , , ,
Read the full story »
[ by | Aug 27, 2014 9:52 pm | 6 Comments ]
OncoPep Begins Sponsorship Of The Myeloma Beacon

OncoPep, a biotech company developing a potential therapeutic vaccine for multiple myeloma, is the Myeloma Beacon’s newest pharmaceutical industry sponsor.

OncoPep was founded in 2010 to develop novel cancer immunotherapies that stimulate a patient’s own immune system to attack cancer cells. The company’s first investigational immuno­therapy is PVX-410, a cancer vac­cine based on re­search in the laboratory of Dr. Kenneth Anderson and Dr. Nikhil Munshi at the Dana-Farber Cancer Institute in Boston.

“OncoPep’s decision to support The Myeloma Beacon is …

Tags: , , ,
Read the full story »
[ by | Aug 17, 2014 4:10 pm | 5 Comments ]
Kyprolis Fails To Provide Overall Survival Benefit In FOCUS Phase 3 Trial

Amgen has given a first glimpse of key results from its FOCUS Phase 3 clinical trial testing Kyprolis in relapsed and refractory multiple myeloma patients.

The company reported this past Wednesday that Kyprolis did not provide an overall survival advantage in the trial, which is being con­ducted out­side the United States.

In addition, the company noted that patients treated with Kyprolis during the trial experienced more kidney-related side effects than patients who were not treated with the drug.

Up until …

Tags: , ,
Read the full story »
[ by | Aug 11, 2014 4:48 pm | 22 Comments ]
Remembering Stephen Kramer

Another valued voice of the myeloma community has been lost.

Stephen P. Kramer, author of the Beacon column “Manhattan Tales,” passed away last Friday, August 8, at Memorial Sloan-Kettering Cancer Center in New York City. Stephen was 66 years old, and was diagnosed with multiple myeloma in early 2010.

At the time of his diagnosis, Stephen was working as Chief of Staff and Special Counsel to the Commissioner of the New York City Department of Buildings. This position was the …

Tags: ,
Read the full story »
[ by | Aug 6, 2014 3:57 pm | One Comment ]
CPI-0610 To Be Tested As Potential Multiple Myeloma Therapy

Constellation Pharmaceuticals recently initiated a Phase 1 clinical trial that will test whether single-agent CPI-0610 is safe and effective as an anti-myeloma therapy.

The clinical trial is taking place at a several locations across the United States, and is open to multiple myeloma patients who have relapsed after at least one previous myeloma treatment regimen.

CPI-0610 is a small molecule that inhibits bromodomain and extra-terminal (BET) proteins, which are involved in regulating the cell cycle and cell death. Bromodomain inhibitors, …

Tags: , , ,
Read the full story »